Lv2
116 积分 2022-05-05 加入
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
9天前
已完结
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
9天前
已完结
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
13天前
已完结
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
13天前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
13天前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
1个月前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
1个月前
已完结
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
1个月前
已完结
The story of amylin: from physiology to therapy
3个月前
已完结
Learning motif-based graphs for drug–drug interaction prediction via local–global self-attention
3个月前
已完结
皖公网安备34019202002308
